loading page

Research progress on the role of zinc finger protein in colorectal cancer
  • +5
  • TANG YU,
  • jiumei zhao,
  • Ziwei Li,
  • Chenglong Pan,
  • Jialing Liu,
  • Kepu Zheng,
  • XiaoHao Wang,
  • Yan Zhang
TANG YU
Yunnan Cancer Hospital
Author Profile
jiumei zhao
Chongqing Nanchuan District People's Hospital
Author Profile
Ziwei Li
Chongqing Health Center for Women and Children
Author Profile
Chenglong Pan
First Affiliated Hospital of Kunming Medical University
Author Profile
Jialing Liu
Yunnan Cancer Hospital
Author Profile
Kepu Zheng
First Affiliated Hospital of Kunming Medical University Department of Oncology
Author Profile
XiaoHao Wang
The Second Affiliated Hospital of Chongqing Medical University
Author Profile
Yan Zhang
The Second Affiliated Hospital of Chongqing Medical University

Corresponding Author:zhangyan@hospital.cqmu.edu.cn

Author Profile

Abstract

Colorectal cancer is one of the most prevalent malignancies worldwide, with a tendency of increasing incidence in developed countries, which poses a significant threats to the patients’ physical and mental health. The development of colorectal cancer involves numerous genetic alterations, which indicate that transcription factors may play an important role in this process. Changes in the level of zinc finger proteins, the most prevalent transcription factor, may play an important trigger for the development of colorectal cancer. Different zinc finger proteins play different roles in terms of promoting or inhibiting cancer development. This paper briefly reviews the classification, functional characteristics, and expression changes of zinc finger proteins in colorectal cancer, it focuses on how they regulate gene transcription, influence on common signaling pathways and their potential for translational studies and clinical applications. The objective is to stimulate new ideas for their study in colorectal cancer while also providing foundational information to guide drug development and treatment strategies for colorectal cancer patients in clinical settings.
09 May 2024Submitted to Cancer Reports
14 Jul 2024Review(s) Completed, Editorial Evaluation Pending
05 Aug 2024Editorial Decision: Revise Major
25 Aug 20241st Revision Received
26 Aug 2024Submission Checks Completed
26 Aug 2024Assigned to Editor
26 Aug 2024Review(s) Completed, Editorial Evaluation Pending
09 Sep 2024Reviewer(s) Assigned